Jerome Durso, Intercept Pharmaceuticals CEO

In­ter­cep­t's OCA fails a PhI­II NASH tri­al, rais­ing fresh doubts about its years­long quest for an OK

In­ter­cept Phar­ma­ceu­ti­cals has run in­to an­oth­er big set­back in its years­long quest to win an ap­proval for OCA in NASH. The biotech put out word …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.